MSD | Cancer | CVD | |

Average annual research investment (for years of data used in IRR calculation as reported in source publications, using different time period for calculating constant prices and therefore not suitable for comparisons) | £70 million (1978–1997, in constant 2013/2014 prices) | £266 million (1976–1995, in constant 2011/2012 prices) | £111 million (1975–1998, in constant 2005/2006 prices) |

Average annual research investment (rebased in same constant prices for comparative purposes) | £70 million (1978–1997, in constant 2013/2014 prices) | £290 million (1976–1995, in constant 2013/2014 prices) | £133 million (1975–1998, in constant 2013/2014 prices) |

Elapsed time (between spending on research and health gain) | 16 years | 15 years | 17 years |

Attribution (proportion of papers that include a UK address from the papers cited on guidelines) | 30% | 17% | 17% |

Average net monetary benefit (NMB) (for years of data used in IRR calculation as reported in source publications, but using different time period for calculating constant prices therefore not suitable for comparisons) | £801 million (1994–2013, in constant 2013/2014 prices) | £6223 million (1991–2010, in constant 2011/2012 prices) | £2949 million (1992–2005, in constant 2005/2006 prices) |

Average NMB (rebased in same constant prices for comparative purposes) | £801 million (1994–2013, in constant 2013/2014 prices) | £6458 million (1991–2010, in constant 2013/2014 prices) | £3559 million (1992–2005, in constant 2013/2014 prices) |

IRR (health gain) | 7% | 10% | 9% |

CVD, cardiovascular disease; IRR, internal rate of return; MSD, musculoskeletal disease.